دورية أكاديمية
أعرض في EDS

Systematic assessment of the influence of quality of studies on mistletoe in cancer care on the results of a meta-analysis on overall survival.

التفاصيل البيبلوغرافية
العنوان: Systematic assessment of the influence of quality of studies on mistletoe in cancer care on the results of a meta-analysis on overall survival.
المؤلفون: Hofinger J; Klinik für Innere Medizin II, Hämatologie und Onkologie, Universitätsklinikum Jena, Jena, Germany. jorina.hofinger@outlook.de., Kaesmann L; Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Ludwig-Maximilians-Universität München, Munich, Germany., Buentzel J; Klinik für Hals‑Nasen‑Ohren‑Heilkunde, Südharzklinikum, Nordhausen, Germany., Scharpenberg M; Kompetenzzentrum Für Klinische Studien, Universität Bremen, Bremen, Germany., Huebner J; Klinik für Innere Medizin II, Hämatologie und Onkologie, Universitätsklinikum Jena, Jena, Germany.
المصدر: Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2024 Apr 29; Vol. 150 (4), pp. 219. Date of Electronic Publication: 2024 Apr 29.
نوع المنشور: Journal Article; Meta-Analysis
اللغة: English
بيانات الدورية: Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 7902060 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-1335 (Electronic) Linking ISSN: 01715216 NLM ISO Abbreviation: J Cancer Res Clin Oncol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Berlin ; New York : Springer-Verlag.
مواضيع طبية MeSH: Mistletoe* , Neoplasms*/mortality , Neoplasms*/drug therapy , Neoplasms*/therapy, Humans ; Meta-Analysis as Topic ; Phytotherapy/methods ; Randomized Controlled Trials as Topic
مستخلص: Purpose: Mistletoe treatment in cancer patients is controversial, and a Cochrane review concluded that due to heterogeneity, performing a meta-analysis was not suitable. However, several systematic reviews included meta-analyses in favor of mistletoe. The aim of this work was to assess the influence of the methodological quality of controlled studies on the results of a meta-analysis regarding overall survival.
Methods: Between April and August 2022, Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), PsycINFO, CINAHL and Web of Science were systematically searched. In addition, reference lists of previously published meta-analyses were checked for relevant publications. A random effects meta-analysis with clustering was performed. The risk of bias within the studies was assessed using ROB 2.0 and ROBINS-I.
Results: The search identified 4685 hits, and 28 publications reporting on 28 298 patients were included in the quantitative analysis. Overall, the analysis led to a significant result in favor of mistletoe therapy (overall HR = 0.61 with 95% CI [0.53;0.7]). According to our subgroup analysis of randomized studies, studies of higher quality (lower risk of bias) did not lead to a significant result in favor of mistletoe therapy (HR = 0.78; CI = [0.30; 2.00]).
Conclusions: In the case of mistletoe therapy, the results of the meta-analysis strongly depended on the methodological quality of the included studies. Calculating meta-analyses that include low-quality studies may lead to severe misinterpretation of the data.
(© 2024. The Author(s).)
References: Arzneimittelforschung. 2005;55(1):38-49. (PMID: 15727163)
Eur J Med Res. 2006 Nov 30;11(11):485-95. (PMID: 17182361)
Altern Ther Health Med. 2001 May-Jun;7(3):57-66, 68-72, 74-6 passim. (PMID: 11347286)
Anticancer Res. 2014 Feb;34(2):943-8. (PMID: 24511037)
Anticancer Res. 2018 Mar;38(3):1585-1593. (PMID: 29491089)
J Cancer Res Clin Oncol. 2019 Sep;145(9):2409-2410. (PMID: 31302756)
Dtsch Med Wochenschr. 2005 Jul 8;130 Suppl 2:S86-90. (PMID: 15988675)
Onkologie. 1979 Feb;2(1):28-36. (PMID: 392367)
Arzneimittelforschung. 2007;57(10):665-78. (PMID: 18074761)
Eur J Med Res. 2008 Mar 31;13(3):107-20. (PMID: 18499556)
Forsch Komplementmed. 2006 Oct;13(5):285-92. (PMID: 17057389)
Integr Cancer Ther. 2022 Jan-Dec;21:15347354221133561. (PMID: 36324298)
Forsch Komplementmed. 2007 Jun;14(3):140-7. (PMID: 17596694)
Eur J Cancer. 2013 Dec;49(18):3788-97. (PMID: 23890767)
PLoS Med. 2009 Jul 21;6(7):e1000097. (PMID: 19621072)
Med Klin. 1967 Feb 24;62(8):305-7. (PMID: 4297248)
Explore (NY). 2012 Sep-Oct;8(5):277-81. (PMID: 22938746)
BMC Cancer. 2009 Dec 18;9:451. (PMID: 20021637)
Trials. 2007 Jun 07;8:16. (PMID: 17555582)
Evid Based Complement Alternat Med. 2010 Jun;7(2):157-66. (PMID: 18955332)
Sarcoma. 2020 Apr 26;2020:8260730. (PMID: 32398946)
Support Care Cancer. 2022 Aug;30(8):6405-6418. (PMID: 35239008)
Curr Mol Med. 2010 Jun;10(4):430-9. (PMID: 20455850)
Res Synth Methods. 2010 Apr;1(2):97-111. (PMID: 26061376)
BMJ. 2016 Oct 12;355:i4919. (PMID: 27733354)
Cochrane Database Syst Rev. 2008 Apr 16;(2):CD003297. (PMID: 18425885)
Pediatr Res. 2022 Jun 14;:. (PMID: 35701608)
Helv Chir Acta. 1977 Jun;44(3):403-14. (PMID: 617173)
J Cancer Res Clin Oncol. 2023 Aug;149(9):5559-5571. (PMID: 36481925)
BMC Complement Med Ther. 2020 Jul 20;20(1):227. (PMID: 32690087)
BMC Cancer. 2022 Jun 13;22(1):652. (PMID: 35698215)
GMS Health Technol Assess. 2006 Sep 19;2:Doc18. (PMID: 21289969)
Eur J Cancer. 2004 Feb;40(3):390-402. (PMID: 14746858)
Complement Med Res. 2020;27(4):260-271. (PMID: 31927541)
J Cancer Res Clin Oncol. 2019 Mar;145(3):695-707. (PMID: 30673873)
فهرسة مساهمة: Keywords: Cancer; Meta-analysis; Methodological quality; Mistletoe therapy; Overall survival; Risk of bias
تواريخ الأحداث: Date Created: 20240428 Date Completed: 20240428 Latest Revision: 20240625
رمز التحديث: 20240625
مُعرف محوري في PubMed: PMC11056339
DOI: 10.1007/s00432-024-05742-1
PMID: 38679615
قاعدة البيانات: MEDLINE
الوصف
تدمد:1432-1335
DOI:10.1007/s00432-024-05742-1